Skip to main content

Table 1 Demographic and clinical features between PD patients with and without FT

From: Facial tremor in patients with Parkinson’s disease: prevalence, determinants and impacts on disease progression

  Total
(n = 2224)
With FT
(n = 403)
Without FT
(n = 1821)
P-value
Education 9.5 ± 4.1 9.0 ± 4.3 9.6 ± 4.0 0.016*
Sex, male 1181 (53.1%) 171 (42.4%) 1010 (55.5%) < 0.001*
Age 62.3 ± 9.9 65.4 ± 9.7 61.6 ± 9.9 < 0.001*
Age at onset 58.9 ± 9.9 60.8 ± 10.1 58.5 ± 9.9 < 0.001*
Disease duration 3.4 ± 3.4 4.5 ± 4.2 3.1 ± 3.1 < 0.001*
LEDD 232.0 ± 275.7 241.6 ± 310.0 229.9 ± 267.6 0.485
UPDRS-IIIa 29.2 ± 14.2 32.5 ± 17.4 28.4 ± 13.3 < 0.001*
Speech 0.7 ± 0.7 0.8 ± 0.8 0.7 ± 0.7 < 0.001*
Facial expression 1.5 ± 0.8 1.5 ± 0.9 1.5 ± 0.8 0.215
Tremor at resta 2.2 ± 2.4 3.3 ± 2.9 1.9 ± 2.1 < 0.001*
Action or postural tremor 1.6 ± 1.4 2.2 ± 1.9 1.4 ± 1.3 < 0.001*
Rigidity 8.0 ± 3.9 8.1 ± 4.4 8.0 ± 3.8 0.607
Bradykinesia 12.3 ± 6.8 13.2 ± 7.7 12.0 ± 6.6 < 0.001*
Axial symptoms 3.0 ± 2.7 3.3 ± 3.1 2.9 ± 2.5 0.006*
H&Y stage 2.0 (0.5) 2.0 (0.5) 2.0 (0.5) 0.025*
Freezing of gait 462 (20.8%) 95 (23.6%) 367 (20.2%) 0.126
Falls 151 (6.8%) 32 (7.9%) 119 (6.5%) 0.310
Motor fluctuation 212 (9.5%) 88 (14.7%) 340 (12.2%) 0.087
Dyskinesia 76 (3.4%) 33 (5.5%) 169 (6.0%) 0.623
FAB 15.2 ± 2.7 14.8 ± 2.8 15.3 ± 2.7 0.001*
MoCA 22.9 ± 4.8 22.0 ± 5.1 23.1 ± 4.7 < 0.001*
HDRS 9.4 ± 8.2 9.8 ± 8.1 9.3 ± 8.2 0.244
Depression 727 (32.7%) 145 (36.0%) 582 (32.0%) 0.120
HARS 7.2 ± 6.6 7.3 ± 6.7 7.1 ± 6.6 0.631
Anxiety 653 (29.4%) 128 (33.8%) 525 (30.8%) 0.242
NMSS 35.7 ± 30.5 39.0 ± 32.9 34.9 ± 29.9 0.024*
  1. PD Parkinson’s disease, FT Facial tremor, LEDD Levodopa Equivalent Daily Doses, UPDRS Unified PD Rating Scale, H&Y stage Hoehn and Yahr stage, FAB Frontal Assessment Battery, MoCA Montreal Cognitive Assessment, HDRS Hamilton Depression Rating Scale, HARS Hamilton Anxiety Rating Scale, NMSS Non-Motor Symptoms Scale
  2. aThe total score was calculated after excluding the score of FT at rest
  3. * Significant difference